Physician profile
Arslan Talat
NPI 1609254044
$979.91
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.93 · 2023: $375 · 2024: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.99 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.34 | 2023-2024 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $176.78 | 2023-2024 | Entyvio |
| Fujifilm Healthcare Americas Corporation | $112.79 | 2023 | Fujifilm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.24 | 2023-2024 | Xifaxan |
| Celltrion USA INC. | $74.99 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $71.59 | 2024 | Dupixent |
| Qol Medical, LLC | $54.23 | 2024 | Sucraid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.63 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $19.54 | 2023 | Voquezna |
| Fresenius Kabi USA, LLC | $17.51 | 2023 | Idacio |
| Pfizer INC. | $16.34 | 2024 | |
| Apollo Endosurgery US INC | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Talat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.